Copyright ©The Author(s) 2018.
World J Gastroenterol. Aug 28, 2018; 24(32): 3583-3616
Published online Aug 28, 2018. doi: 10.3748/wjg.v24.i32.3583
Figure 1
Figure 1 The three phases of cancer immunoediting. A: Phase 1: Elimination; B: Phase 2: Equilibrium; C: Phase 3: Escape. NK: Natural killer cells; Th: T helper lymphocyte; Tc: T cytotoxic lymphocyte; T reg: Regulatory T lymphocyte; DC: Dendritic cell; CC: Cancer cell.
Figure 2
Figure 2 Current immunotherapeutic strategies in gastric cancer. NK: Natural killer cells; TILs: Tumor-infiltrating lymphocytes; CIK: Cytokine-induced killer cells; ACT: Adoptive cell therapy; DCs: Dendritic cells; PD-1: Programmed death-1; PD-L1: Programmed death ligand-1; CTLA-4: Cytotoxic T-lymphocyte-associated antigen 4; CI: Checkpoint inhibitors.
Figure 3
Figure 3 Therapeutic algorithm in unresectable locally advanced, recurrent or metastatic gastric cancer. HER2: Human epidermal growth factor receptor 2; CX: Cisplatin and capecitabine; CF: Cisplatin and fluorouracil; MSI: Microsatellite instability; dMMR: Deficient mismatch repair gene; PD-L1: Programmed death ligand-1.